# Celldex Therapeutics clinical trials: 45 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials with Celldex Therapeutics as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Celldex Therapeutics: 45 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/celldex-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 9, 2026 | NCT07330778 | A Study of CDX-622 in Participants With Mild to Moderate Asthma | Celldex Therapeutics | Phase 1 | Recruiting | Mild to Moderate Asthma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330778) |
| December 5, 2025 | NCT07266402 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and... | Celldex Therapeutics | Phase 3 | Recruiting | Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07266402) |
| December 1, 2025 | NCT07256392 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Celldex Therapeutics | Phase 3 | Enrolling by invitation | Chronic Spontaneous Urticaria | 1,370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07256392) |
| December 11, 2024 | NCT06727552 | A Study of Barzolvolimab in Patients With Atopic Dermatitis | Celldex Therapeutics | Phase 2 | Active not recruiting | Atopic Dermatitis | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06727552) |
| October 21, 2024 | NCT06650761 | A Phase I Study of CDX-622 | Celldex Therapeutics | Phase 1 | Completed | Healthy Participants | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06650761) |
| June 12, 2024 | NCT06455202 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Celldex Therapeutics | Phase 3 | Active not recruiting | Chronic Spontaneous Urticaria | 976 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06455202) |
| June 6, 2024 | NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Celldex Therapeutics | Phase 3 | Active not recruiting | Chronic Spontaneous Urticaria | 963 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06445023) |
| April 16, 2024 | NCT06366750 | A Study of Barzolvolimab in Patients With Prurigo Nodularis | Celldex Therapeutics | Phase 2 | Active not recruiting | Prurigo Nodularis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06366750) |
| March 29, 2023 | NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | Celldex Therapeutics | Phase 1 | Completed | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05788484) |
| March 17, 2023 | NCT05774184 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | Celldex Therapeutics | Phase 2 | Completed | Eosinophilic Esophagitis | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05774184) |
| June 6, 2022 | NCT05405660 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | Celldex Therapeutics | Phase 2 | Completed | Chronic Inducible Urticaria | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05405660) |
| May 10, 2022 | NCT05368285 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Celldex Therapeutics | Phase 2 | Completed | Chronic Spontaneous Urticaria | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05368285) |
| September 2, 2021 | NCT05031624 | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | Celldex Therapeutics | Phase 1 | Completed | Healthy Subjects | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05031624) |
| June 30, 2021 | NCT04944862 | A Study of CDX-0159 in Patients With Prurigo Nodularis | Celldex Therapeutics | Phase 1 | Completed | Prurigo Nodularis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04944862) |
| September 16, 2020 | NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic... | Celldex Therapeutics | Phase 1 | Completed | Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism, Symptomatic Dermatographism, Cholinergic Urticaria | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04548869) |
| September 4, 2020 | NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Celldex Therapeutics | Phase 1 | Completed | Chronic Spontaneous Urticaria | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04538794) |
| June 22, 2020 | NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | Celldex Therapeutics | Phase 1 | Completed | Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04440943) |
| October 31, 2019 | NCT04146129 | A Phase 1 Study of CDX-0159 | Celldex Therapeutics | Phase 1 | Completed | Healthy Subjects | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04146129) |
| November 6, 2017 | NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | Celldex Therapeutics | Phase 1 | Completed | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03329950) |
| August 21, 2017 | NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | Celldex Therapeutics | Phase 2 | Terminated | Advanced Head and Neck Squamous Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03254927) |
| March 3, 2017 | NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut | Celldex Therapeutics | Not applicable | No longer available | Recurrent GBM | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03068650) |
| March 1, 2017 | NCT03067935 | Individual Patient Expanded Access-Glembatumumab Vedotin | Celldex Therapeutics | Not applicable | No longer available | Metastatic gpNMB Expressing Triple Negative Breast Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03067935) |
| July 20, 2016 | NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | Celldex Therapeutics | Phase 1 | Terminated | Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02837991) |
| December 30, 2015 | NCT02642016 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors | Celldex Therapeutics | Phase 1 | Completed | Advanced Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02642016) |
| September 7, 2015 | NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Celldex Therapeutics | Phase 1 | Terminated | Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02543645) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 1/2 | 3 |
| Phase 2 | 13 |
| Phase 3 | 5 |
| Not applicable | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 9 |
| Active not recruiting | 4 |
| Recruiting | 2 |
| No longer available | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Renal Cell | 8 |
| Ovarian Neoplasms | 8 |
| Breast Neoplasms | 7 |
| Melanoma | 6 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Chronic Urticaria | 5 |
| Colorectal Neoplasms | 5 |
| Urinary Bladder Neoplasms | 5 |
| Kidney Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Head and Neck Neoplasms | 4 |
| Pancreatic Neoplasms | 4 |
| Neoplasms | 4 |
| Glioblastoma | 4 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Kidney Diseases | 3 |
| Stomach Neoplasms | 3 |
| Cholangiocarcinoma | 3 |
| Liver Neoplasms | 3 |
| Fallopian Tube Neoplasms | 3 |
| Urogenital Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 2 |
| Chronic Inducible Urticaria | 2 |
| Cold Urticaria | 2 |
| Familial dermographism | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
- [Aesthetic medicine clinics in the United States](https://specstream.ai/data/businesses/aesthetic-medicine-clinics/united-states)
- [College counseling companies in the United States](https://specstream.ai/data/businesses/college-counseling-companies/united-states)
- [Guest houses in the United States](https://specstream.ai/data/businesses/guest-houses/united-states)
